{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(5)"],"submitter":["Nesaretnam K"],"pubmed_abstract":["<h4>Introduction</h4>Basic research has indicated that tocotrienols have potent antiproliferative and proapoptotic effects that would be expected to reduce the effect of breast cancer.<h4>Methods</h4>We conducted a double-blinded, placebo-controlled pilot trial to test the effectiveness of adjuvant tocotrienol therapy in combination with tamoxifen for five years in women with early breast cancer. Two-hundred-forty women, aged between 40-60 years, with either tumor node metastases (TNM) Stage I or II breast cancer and estrogen receptor (ER) positive tumors were non-randomly assigned to two groups. The intervention group received tocotrienol rich fraction (TRF) plus tamoxifen whilst the control group received placebo plus tamoxifen, for five years.<h4>Results</h4>During the five years of stu"],"journal":["Breast cancer research : BCR"],"pagination":["R81"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3096974"],"repository":["biostudies-literature"],"pubmed_title":["Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial."],"pmcid":["PMC3096974"],"pubmed_authors":["Nesaretnam K","Selvaduray KR","Gomez PA","Abdul Razak G","Veerasenan SD"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial.","description":"<h4>Introduction</h4>Basic research has indicated that tocotrienols have potent antiproliferative and proapoptotic effects that would be expected to reduce the effect of breast cancer.<h4>Methods</h4>We conducted a double-blinded, placebo-controlled pilot trial to test the effectiveness of adjuvant tocotrienol therapy in combination with tamoxifen for five years in women with early breast cancer. Two-hundred-forty women, aged between 40-60 years, with either tumor node metastases (TNM) Stage I or II breast cancer and estrogen receptor (ER) positive tumors were non-randomly assigned to two groups. The intervention group received tocotrienol rich fraction (TRF) plus tamoxifen whilst the control group received placebo plus tamoxifen, for five years.<h4>Results</h4>During the five years of stu","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010","modification":"2025-04-18T23:31:43.13Z","creation":"2019-03-27T00:41:42Z"},"accession":"S-EPMC3096974","cross_references":{"pubmed":["20929592"],"doi":["10.1186/bcr2726"]}}